Thermo Fisher Scientific (TMO) to Release Quarterly Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $5.11 per share and revenue of $10.23 billion for the quarter. Thermo Fisher Scientific has set its FY 2025 guidance at 23.100-23.500 EPS.Parties that wish to listen to the company's conference call can do so using this link.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, analysts expect Thermo Fisher Scientific to post $23 EPS for the current fiscal year and $26 EPS for the next fiscal year.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $10.68 during mid-day trading on Friday, hitting $426.11. The company had a trading volume of 3,037,150 shares, compared to its average volume of 1,715,026. Thermo Fisher Scientific has a 12 month low of $409.85 and a 12 month high of $627.88. The stock's fifty day moving average price is $497.67 and its two-hundred day moving average price is $533.64. The firm has a market cap of $160.85 billion, a PE ratio of 25.78, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.40%. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on TMO shares. Citigroup decreased their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Barclays reduced their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Scotiabank upped their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Finally, Raymond James reissued an "outperform" rating and issued a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $642.67.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now directly owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

A hedge fund recently raised its stake in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 491 shares of the medical research company's stock after purchasing an additional 20 shares during the quarter. Revolve Wealth Partners LLC's holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.